Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

baxter healthcare (malaysia) sdn. bhd. - sodium lactate usp; dextrous hydrous usp; calcium chloride usp; sodium chloride usp; magnesium chloride usp -

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

baxter healthcare (malaysia) sdn. bhd. - dextrose, hydrous, usp; sodium lactate usp; calcium chloride usp; sodium chloride usp; magnesium chloride usp -

Singapur - anglès - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - the solution administration set will be used to administer fluids to a patient's vascular system from a container through a needle or catheter inserted into a vein. the proposed solution set will be primarily used to administer solutions containing the chemotherapeutic drug paclitaxel and also used for general solution administration with baxter flo-gard and colleague volumetric infusion pumps.

Singapur - anglès - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - magnesium chloride; potassium chloride; sodium acetate trihydrate; sodium chloride; sodium gluconate - injection - 30 mg/100 ml - magnesium chloride 30 mg/100 ml; potassium chloride 37 mg/100 ml; sodium acetate trihydrate 368 mg/100 ml; sodium chloride 526 mg/100 ml; sodium gluconate 502 mg/100 ml

Singapur - anglès - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - dextrose hydrous; potassium chloride; sodium chloride - injection - 50 g/l - dextrose hydrous 50 g/l; potassium chloride 1.5 g/l; sodium chloride 3.3 g/l

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 10% - solution for infusion - 10 % - active: glucose monohydrate 10% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 25% - solution for infusion - 25 % - active: glucose monohydrate 25% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 5% - solution for infusion - 5 % - active: glucose monohydrate 5% - isotonic (glucose 5%) infusion solutions are mainly indicated for: - whenever non-electrolyte fluid replacement is required, - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 50% - solution for infusion - 50 % - active: glucose monohydrate 50% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 70% - solution for infusion - 70 % - active: glucose monohydrate 70% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.